Results 111 to 120 of about 12,810 (265)

Reaching the Unreachable: Marketing a Virtual Memory Clinic for Older Adults With Dementia in Rural and Underserved Areas

open access: yes
Journal of the American Geriatrics Society, EarlyView.
Jennifer Woodward   +2 more
wiley   +1 more source

Kaempferol Improves Alzheimer's Disease by Inhibiting Neuronal Ferroptosis via Activating GPX4/AKR1C3 Signaling Pathway

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Kaempferol has been shown to be beneficial in the treatment of Alzheimer's disease (AD) in animal models. However, the action mechanism remains unclear. AKR1B1 has been identified as a target of kaempferol, initially suggested by the Therapeutic Target Database, DrugBank, and PubChem, and subsequently confirmed through experimental validation.
Le Li   +5 more
wiley   +1 more source

Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, yet whether established clinical DPN is reversible remains debated. At the 35th Annual Meeting of NEUROdiab, a formal debate examined arguments ‘for’ and ‘against’ the proposition that clinical DPN can be reversed.
Gordon Sloan   +9 more
wiley   +1 more source

Effect of pH on Blepharisma intermedium. 5. Studies on esterases [PDF]

open access: yes, 1977
Synopsis. Esterases of Blepharisma intermedium grown in buffered media of different pH values and in unbuffered media have been char­acterized. Selective inhibition studies indicate six carboxylesterases, two arylesterases and one cholinesterase in all ...
Jyothy, P.S., Shadaksharaswamy, M.
core  

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

open access: yesJournal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira   +9 more
wiley   +1 more source

Chem Biol Interact [PDF]

open access: yes
Organophosphorus (OP) compounds include a broad group of toxic chemicals such as insecticides, chemical warfare agents and antiwear agents. The liver cytochromes P450 bioactivate many OPs to potent inhibitors of serine hydrolases.

core  

Design, Synthesis, and Evaluation of Coumarin‐Rasagiline Hybrids as Multifunctional Neuroprotective Agents

open access: yesChemMedChem, Volume 21, Issue 10, 27 May 2026.
Novel coumarin‐rasagiline hybrid molecules were designed and synthesized as multifunctional agents targeting key pathological mechanisms of neurodegenerative diseases. These compounds exhibited hMAO‐B inhibitory activity, antioxidant and neuroprotective effects, supported by ADMET profiling and molecular modeling studies. The design of hybrid molecules
Aitor Carneiro   +8 more
wiley   +1 more source

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

open access: yesAdvanced Science, Volume 13, Issue 27, 13 May 2026.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy